The safety and effectiveness of MUC1-targeted CAR-T cell treatment in patients with MUC1-positive advanced refractory solid tumors, such as HNSCC, are being examined by the Phase I clinical study NCT03013712. Here, MUC1 is linked to head and neck squamous cell carcinoma.